SCHEMBL3149568

SCHEMBL3149568

CCN(CC)CCOc1ccc(C(C)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EBP Q15125 3/20 0.69
SIGMAR1 Q99720 3/20 0.69
L3MBTL1 Q9Y468 1/20 0.66
GAA P10253 1/20 0.64
MAOB P27338 1/20 0.62
LMNA P02545 1/20 0.61
SCN1A P35498 1/20 0.61
SCN2A Q99250 1/20 0.61
SCN3A Q9NY46 1/20 0.61
BCHE P06276 1/20 0.59
ACHE P22303 1/20 0.59
HRH3 Q9Y5N1 2/20 0.58
ESR1 P03372 5/20 0.57
KCNH2 Q12809 2/20 0.57
CHRM2 P08172 2/20 0.57
ADRA2A P08913 2/20 0.57
ADORA3 P0DMS8 2/20 0.57
CHRM1 P11229 2/20 0.57
PTGS1 P23219 2/20 0.57
SLC6A2 P23975 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491797 0.92 L3MBTL1 (0.69) EBPSIGMAR1L3MBTL1GAAMAOB
SCHEMBL250102 0.87 EBP (0.69) EBPSIGMAR1LMNASCN1ASCN2A
Hydrochloric Acid SCHEMBL4465808 0.85 EBP (0.67) EBPSIGMAR1LMNASCN1ASCN2A
SCHEMBL6812378 0.85 EBP (0.67) EBPSIGMAR1MAOBLMNASCN1A
SCHEMBL10885211 0.85 EBP (0.71) EBPSIGMAR1MAOBLMNASCN1A
SCHEMBL5418720 0.85 EBP (0.67) EBPSIGMAR1MAOBLMNASCN1A
Hydrochloric Acid SCHEMBL11673068 0.84 EBP (0.65) EBPSIGMAR1MAOBLMNASCN1A
SCHEMBL4473605 0.84 MAPT (0.70) EBPSIGMAR1L3MBTL1LMNASCN1A
SCHEMBL9706125 0.84 EBP (0.72) EBPSIGMAR1HRH3ESR1KCNH2
SCHEMBL4703442 0.83 EBP (0.59) EBPSIGMAR1MAOBLMNASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 EP disclosed
EP-1511742-B1 KINASE INHIBITORS CYTOPIA RES PTY LTD (AU) 2010-02-03 EP disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 US disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 US disclosed
US-7598272-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-10-06 US disclosed
US-7511047-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-03-31 US disclosed
US-7511047-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-03-31 US disclosed
US-7511047-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2009-03-31 US disclosed
US-7259179-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-08-21 US disclosed
US-7259179-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-08-21 US disclosed
US-7259179-B2 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-08-21 US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 US disclosed
US-20070161635-A1 Kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2007-07-12 US disclosed
US-20060270687-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-11-30 US disclosed
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-10-26 US disclosed
EP-1511742-A1 KINASE INHIBITORS Cytopia PTY Ltd (AU) 2005-03-09 EP disclosed
US-20050004140-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2005-01-06 US disclosed
WO-2003099811-A1 KINASE INHIBITORS CYTOPIA PTY LTD (AU) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270687-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 EBP 2943/4885SIGMAR1 3848/4885L3MBTL1 2395/4885
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states MAP4K2, MAP4K5, MAP4K4 EBP 1937/4885SIGMAR1 2765/4885L3MBTL1 1758/4885
US-20050004140-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 EBP 2943/4885SIGMAR1 3848/4885L3MBTL1 2395/4885
US-20070161635-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K10 EBP 3475/4885SIGMAR1 3752/4885L3MBTL1 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.